Hormone replacement therapy and malignant tumors

Abstract

The review on malignant tumors morbidity and its risk during hormone replacement therapy (HRT) is shown. The questions on possibilities of HRT in oncologic patients and the results of successful HRT management in rehabilitation of cervical cancer patients after surgical and and combined treatment are discussed.

Keywords

hormone replacement therapy / malignant tumors / cervical cancer

References

[1] Моисеенко В.М., Семиглазов В.Ф., Тюляндин С.А. Современное лекарственное лечение местнораспространенного и метастатического рака молочной железы. - СПб., Трифон”.- 1997.-254 с.

[2] Семиглазов В.Ф. Проблемы рака молочной железы на пороге XXI века (актовая речь, посвященная 70-летию образования НИИ онкологии им. проф. Н.Н. Петрова МЗФ).- СПб.- 1997.- 16 с.

[3] Чиссов В.И., Старинский В.В., Ременник Л.В. Злокачественные новообразования в России в 1997 г. - Москва. - 1999. - 288 с.

[4] Adami Н.О. etal. Risk of cancer in women receiving hormone replacement therapy //Inter. J. Cancer.- 1989.- Vol.44.-P. 833- 9.

[5] Beresford S.A., Weiss N.S., Voigt L.F., McKnight. Risk of endometrial cancer in relation to use of estrogens combined with cyclic progestagen therapy in postmenopausal women// Lancet. - 1997.-Vol. 349.-P. 458-61.

[6] Bluming A.Z., Waisman J.R., Dosik G.A. et al. Hormone replacement therapy (HRT) in women with previously treated primary breast cancer, update IV. // Proc. Am. Soc. Clin. Oncol.- 1998.- Vol. 17.-P. 130.

[7] Colditz G.A., Hankinson S.E., Hunter D.J. et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women// N. Engl. J. Med.- 1995.- Vol. 332.- P. 1589-93.

[8] Di Saia P.J., Grosen, Kurosaki T. et al. Hormone replacement therapy in breast cancer survivors: A cohort study// Am. J. Obstet. Gynecol.- 1996.- Vol. 174.- P. 1494-8.

[9] Early Breast Cancer Trialists’ Collaborative Group Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer// Lancet.-1997.- Vol. 350.-P. 1047-59.

[10] Franceschi S. Replacement therapy in menopause and risk for breast tumors // Ann. 1st Super Sanita.- 1997.- Vol. 33(2).- P. 207-11.

[11] Gambrell R.D. Hormone replacement therapy and breast cancer risk//Arch. Farm. Med.-1996. - Vol. 5(6).-P. 341-8.

[12] Garg P.P., Kerlikowske K., Subak L., Grady D. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis// Obstet. Gynecol. - 1998.- Vol. 92(3).-P. 472-9.

[13] Grady D., Ernster V.L. Hormone replacement therapy and endometrial cancer risk: A meta analysis // Obstet. Gynecol.- 1995. - Vol. 85.- P. 304-13.

[14] Grodstein F, Martinez M.E., Platz E.A. Postmenopausal hormone use and risk for colorectal cancer and adenoma // Ann. Intern. Med.- 1998.- Vol. 128 (9).- P. 705-12.

[15] Guidozzi F, Paponte A. Estrogen replacement therapy in ovarian cancer survivors // Inter. J. Gynec. Cancer.- 1999.- Vol. 9.- P. 5.

[16] Hulka B.S. Links between hormone replacement therapy and neoplasia // Fertil. Steril. - 1994.- Vol. 62(2).- P. 168-75.

[17] Kampman E., Potter J.D., Slattery M.L. etal. Hormone replacement therapy, reproductive history and colon cancer: multicenter, case-control study in the United States// Cancer Causes Control. - 1997.- Vol. 8(2). -P. 146-58.

[18] Lee R.B., Bulka T.W., Park R.C. Estrogen replacement therapy following treatment for stage I endometrial carcinoma// Gynecol. Oncol.- 1990.- Vol. 36.- P. 189-91.

[19] Leung W., Goldberg F., Zee B., Sterns E. Mammographic density in women on postmenopausal hormone replacement therapy//Surgery. -1997. - Vol. 122(4).-P. 669-73.

[20] Levi F., Lucchini F., Pasche C., La Vecchia C. Oral contraceptives, menopausal - Vol. 5(4).- P. 259-66.

[21] Magnusson C., Holmberg L., Norden T. R. et al. Prognosticcharacteristics in breast cancers after hormone replacement therapy// Breast Cancer Res. Treat.- 1996.- Vol. 38(3).-P. 325-34.

[22] Newcomb P.A., Storer B.E. Postmenopausal hormone use and risk of large -bowel cancer (see comments)//J. Natl. Cancer Inst.-1995.-Vol. 87(14).-P. 1067-71.

[23] O’Connor I.F., Shembekar M.V., Shousha S. Breast carcinoma developing in patients on hormone replacement therapy: a histological and immunohistological study//J. Clin. Pathol.- 1998.- Vol. 51 (12).-P. 935-8.

[24] Parazzini F. et al. Case-control study of oestrogen replacement therapy and risk of cervical cancer// Вr. Med. J.- 1997.- Vol. 315. -P. 85-8.

[25] Persson I., Yven J., Bergkvist L., Shairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy: Long-term follow up of a Swedish cohort// Inter. J. Cancer- 1996.- Vol. 67.- P. 327-32.

[26] Peters G.N., Jones S.E. Estrogen replacement in breast cancer patients: time to change? //Proc. 32nd Annual Meeting Amer. Soc. Clin. Oncol.- Vol. 15.- P. 148.

[27] Ploch E. Hormone replacement therapy in patients after cervical cancer treatment// Gynecol. Oncol.- 1987.- Vol. 26.- P. 169-77.

[28] Potter J.D., Bostick R.M., Grandits G.A. et al. Hormone replacement therapy is associated with lower risk of adenomatous polyps of the large bowel: the Minnesota Cancer Prevention Research Unit Case- Control Study// Cancer Epidemiol. Biomarkers Prev. - 1996.- Vol. 5(10).-P. 779-84.

[29] Rakar S. Hormone replacement therapy (HRT) and cancer of the endometrium, cervix, vagina, vulva and non- gynecolocical// Eur. J. Gynecol. Oncol.- 1999.-XX.-P. 7-8.

[30] Roy J.A., Sawka C.A., Pitchard К.I. Hormone replacement therapy in women with breast cancer: do the risks outweigh the benefits? //J. Clin. Oncol.- 1996.- Vol. 14.- P. 997- 1006.

[31] Stanford J.L., Weiss N.S., VoigtL.F. etal. Hormone replacement therapy and breast cancer: what are the facts? // Med. J. Aust.-1995.- Vol. 163 (9).- P. 483-5.

[32] Stoll B.A. Hormone replacement therapy in women treated for breast cancer//Eur. J. Cancer Clin. Oncol.- 1993.- Vol. 25.-P. 1909-13.

[33] Suriano K., McHale M., Re A., Di Saia P. Estrogen replacement therapy in endometrial cancer patients does not increase recurrence risk//Inter. J. Gynec. Cancer.- 1999.- Vol. 9.- P. 83.

[34] Voigt L.F. etal. Progestagen supplementation of exogenous estrogens and risk of endometrial cancer //Lancet. - 1991.- Vol. 338. - P. 274-7.

[35] Wile A.G., Opfell R.W., MagHeth D.A. Hormone replacement therapy in previously treated breast cancer survivors// Am. J. Surg.- 1993.- Vol. 165.- P. 372-5.

RIGHTS & PERMISSIONS

Eсо-Vector